Vergoeding 2015-2019 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Lantus ®) | 51.077.700 | 50.254.700 | 46.570.200 | 43.863.500 | 41.076.300 |
| A10AE05 Insuline detemir (Levemir ®) | 21.269.800 | 17.953.000 | 14.745.500 | 12.205.500 | 10.383.000 |
| A10AE06 Insuline degludec (Tresiba ®) | 901.090 | 7.185.200 | 13.304.900 | 18.504.300 | 19.253.700 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | . | . | 84.925 | 428.860 | 655.720 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | . | . | 1.570.400 | 3.567.200 | 3.517.000 |
| Totaal | 73.248.590 | 75.392.900 | 76.275.925 | 78.569.360 | 74.885.720 |